{"groups":[{"description":"Bendamustine + rituximab in participants with chronic lymphocytic leukemia (CLL) without deletion 17p \\[del(17p)\\]; bendamustine 90 milligrams (mg)/m\\^2/day administered intravenously (IV) on the first 2 days of each cycle for 6 cycles; rituximab 375 mg/m\\^2 for Cycle 1 and 500 mg/m\\^2 for Cycles 2 to 6 (each cycle is 28 days)","id":"FG000","title":"Cohort 1: Bendamustine + Rituximab Without Del(17p)"},{"description":"Zanubrutinib in participants with CLL without del(17p); 160 mg administered twice a day orally until unacceptable toxicity or disease progression","id":"FG001","title":"Cohort 1: Zanubrutinib Without Del(17p)"},{"description":"Zanubrutinib in participants with CLL with del(17p); 160 mg administered twice a day orally until unacceptable toxicity or disease progression","id":"FG002","title":"Cohort 2: Zanubrutinib With Del(17p)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"202"},{"groupId":"FG001","numSubjects":"219"},{"groupId":"FG002","numSubjects":"102"}],"type":"Remained on study at time of data cut-off"},{"reasons":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"16"},{"groupId":"FG002","numSubjects":"8"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"1"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"Lost to Follow-up"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"238"},{"groupId":"FG001","numSubjects":"241"},{"groupId":"FG002","numSubjects":"111"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"227"},{"groupId":"FG001","numSubjects":"240"},{"groupId":"FG002","numSubjects":"111"}],"type":"Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"238"},{"groupId":"FG001","numSubjects":"241"},{"groupId":"FG002","numSubjects":"111"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Available data are presented as of the primary analysis data cut-off date of 07MAY2021; as of the data cut-off date, all cohorts were ongoing."}